An observational study in Allergic Bronchopulmonary Aspergillosis (ABPA), sponsored by Qianfoshan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-04.
Sponsored by Qianfoshan Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Aspergillosis, Allergic Bronchopulmonary with a site in China — 11 open to participants now, 11 under way, none of them phase 3. Aspergillosis, Allergic Bronchopulmonary · China.
Among the 11 studies in Aspergillosis, Allergic Bronchopulmonary with a site in China, this one is one of 5 that started in 2025, is one of 9 observational ones, reaches primary completion later than 5 of the 10 other live ones, and was the 2nd registered.
42 studies on the registry are indexed under Aspergillosis, Allergic Bronchopulmonary; 13 are open to participants now.
Browse Aspergillosis, Allergic Bronchopulmonary studies →11 of the 11 studies in Aspergillosis, Allergic Bronchopulmonary with a site in China are open now. Recruiting first, the newest first:
Qianfoshan Hospital · Sites in China
Ages 18+
Qianfoshan Hospital · Sites in China
Ages 18–75
First Affiliated Hospital of Ningbo University · Sites in China
Ages 18+ · Healthy volunteers
Qianfoshan Hospital · Sites in China
Ages 18+
Qianfoshan Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 10 Aspergillosis, Allergic Bronchopulmonary studies recruiting now, 7 (70%) set no upper age limit and 1 (10%) stops at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 5 started in 2025.
This study's planned enrollment of 140 is above the median of 73 across 14 observational studies indexed under Aspergillosis, Allergic Bronchopulmonary.
Median enrollment 10 across the 2 interventional studies, 140 across the 9 observational. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
None of the 11 has an industry lead sponsor. The 3 most frequent:
Qianfoshan Hospital is the lead sponsor of 144 studies on the registry; 75 are open to participants now.
Qianfoshan Hospital has 9 studies filed under Aspergillosis, Allergic Bronchopulmonary — fewer than ten, so there is no comparison to draw.
3 of the studies in Aspergillosis, Allergic Bronchopulmonary with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07828327Qianfoshan HospitalReal-World Effectiveness of Depemokimab in Allergic Bronchopulmonary Aspergillosis With Severe Eosinophilic Asthma | 2027-02-28 |
| NCT07757841Qianfoshan HospitalReal-World Effectiveness of Tezepelumab in Allergic Bronchopulmonary Aspergillosis | 2027-06-30 |
| NCT07040332Qianfoshan HospitalPathogenesis and Inflammatory Phenotype of Allergic Bronchopulmonary Aspergillosis | 2027-07-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 11 studies in Aspergillosis, Allergic Bronchopulmonary with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to reveal the immune and inflammatory regulatory molecular mechanisms related to the progression of allergic bronchopulmonary aspergillosis (ABPA), and to build a precision typing based on inflammation and identify the biomarkers of typing, and to explore the clinical outcomes of different inflammatory phenotypes.
The patients with allergic bronchopulmonary aspergillosis and fungal-sensitized asthma who were treated in several hospitals were included as the study objects, and the relatively normal ones who had no bronchial asthma and no fungal sensitization were matched by gender and age as the control group, and then the cohorts of patients with allergic bronchopulmonary aspergillosis, fungal-sensitized asthma and the control group were established.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Total serum IgE
Time frame: Up to 12 months
Aspergillus-specific IgE
Time frame: Up to 12 months
Aspergillus-specific IgG
Time frame: Up to 12 months
Plan to share: No
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Jul 2027, 26 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aspergillosis, Allergic Bronchopulmonary →